A COMPARATIVE-ANALYSIS OF THE SENSITIVITY OF MULTIDRUG RESISTANT (MDR) AND NON-MDR CELLS TO DIFFERENT ANTHRACYCLINE DERIVATIVES

被引：38

作者：

MICHIELI, M

MICHELUTTI, A

DAMIANI, D

PIPAN, C

RASPADORI, D

LAURIA, F

BACCARANI, M

机构：

[1] Sections of Hematology, Anatomy and Microbiology, Institute of Experimental and Clinical Morphology, University of Udine School of Medicine, Bologna

[2] Institute of Hematology L. e A. Seràgnoli University of Bologna School of Medicine, Bologna

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 03期

关键词：

ANTHRACYCLINES; MULTIDRUG RESISTANCE; CHEMOTHERAPY;

D O I：

10.3109/10428199309147379

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because of the fact that tumor cell sensitivity to cytotoxic agents may play a major role in cancer treatment, and several anthracyclines are widely used for first-line treatment of leukemia, lymphoma and other tumors, and since the overexpression of the mdr-1 gene-coded 170 Kd glycoprotein (P170) decreases cell sensitivity to anthracyclines, we investigated the relationship between P170 overexpression and the cytotoxicity of two classic anthracyclines (Daunorubicin or DNR and Doxorubicin or DX) and two lipophilic anthracycline derivatives (Idarubicin or IDA and Iododoxorubicin or IDX). For these purposes, we used multidrug resistant (MDR) and non-MDR tumor and leukemia cell lines and the MTT-microcultured tetrazolium colorimetric assay. We showed that mdr-I gene overexpression was strongly associated with the development of a high level of resistance to DNR and DX, but not to the derivatives IDA and IDX. These data suggest that more lipophilic anthracycline derivatives may also be active in MDR cell systems.

引用

页码：255 / 264

页数：10

共 69 条

[1]

Moscow J.A., Cowan K.H., Multidrug resistance, J. Natl. Cancer Inst., 80, pp. 14-20, (1988)

[2]

Kaye S.B., The multidrug resistance phenotype, J. Cancer, 58, pp. 691-694, (1988)

[3]

Nooter K., Herweijer H., Multidrug resistance (mdr) genes in human cancer, Br. J. Cancer, 63, pp. 663-669, (1991)

[4]

Pastan I., Gottesman M., Multiple drug resistance in human cancer, N. Eng. J. Med., 316, pp. 1388-1393, (1987)

[5]

Luk C.K., Tannock I.F., Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines, J. Natl. Cancer Inst., 81, pp. 55-59, (1989)

[6]

Inaba M., Kobayashi H., Sakurai Y., Johnson R.K., Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia, Cancer Res., 39, pp. 2200-2203, (1979)

[7]

Weistein R.S., Kuszak J.R., Kluskens L.F., Coon J.S., P-glycoproteins in pathology: the multidrug resistance gene family in humans, Human Pathol., 21, pp. 34-48, (1990)

[8]

Hitchins R.N., Harman D.H., Davey R.A., Bell D.R., Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues, Eur. J. Cancer Clin. Oncol., 24, pp. 449-454, (1988)

[9]

Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S., Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK-16, Cancer Res., 48, pp. 1926-1929, (1988)

[10]

Cordon-Cardo C., O'Brien J.P., Casals D., Rittmann-Grauer L., Biedler J.L., Melamed M.T., Bertino J.R., Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites, Proc. Natl. Acad. Sci. USA, 86, pp. 695-698, (1989)

← 1 2 3 4 5 6 7 →